Search hospitals > New York > New York
NYU School of Medicine's Kaplan Comprehensive Cancer Center
Claim this profileNew York, New York 10016
Global Leader in Lymphoma
Global Leader in Breast Cancer
Conducts research for Brain Tumor
Conducts research for Solid Tumors
Conducts research for Ovarian Cancer
273 reported clinical trials
6 medical researchers
Summary
NYU School of Medicine's Kaplan Comprehensive Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Lymphoma, Breast Cancer, Brain Tumor, Solid Tumors, Ovarian Cancer and other specialties. NYU School of Medicine's Kaplan Comprehensive Cancer Center is involved with conducting 273 clinical trials across 166 conditions. There are 6 research doctors associated with this hospital, such as Paul Oberstein, MD, Janice M. Mehnert, Kristen Spencer, MD, and Elaine Shum, MD.Area of expertise
1Lymphoma
Global Leader2Breast Cancer
Global LeaderER positive
Stage IV
PR positive
Top PIs
Paul Oberstein, MDNYU Langone Health3 years of reported clinical research
Expert in Pancreatic Cancer
Studies Stomach Cancer
21 reported clinical trials
49 drugs studied
Janice M. MehnertLaura and Isaac Perlmutter Cancer Center at NYU Langone4 years of reported clinical research
Expert in Skin Cancer
Studies Cancer
18 reported clinical trials
26 drugs studied
Kristen Spencer, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Cancer
Studies Uterine Tumors
14 reported clinical trials
46 drugs studied
Elaine Shum, MDNYU Langone Health5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
17 drugs studied
Clinical Trials running at NYU School of Medicine's Kaplan Comprehensive Cancer Center
Skin Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Microsatellite Instability
Melanoma
Relapse
Locoregional Recurrence
Cancer
Lynch Syndrome
Pembrolizumab Combinations
for Melanoma
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to treatment Arm 1: Pembrolizumab + Vibostolimab was added in the base protocol on 13-Nov-2019, and enrollment into this arm has been completed. Arm 2: Pembrolizumab was added in the base protocol on 13-Nov-2019, and enrollment stopped prematurely on 15-Aug-2022. Arm 3: Coformulation Pembrolizumab/Quavonlimab was added in Amendment 01 on 20-Oct-2020, and enrollment stopped prematurely on 15-Aug-2022. Arm 4: Coformulation Pembrolizumab/Quavonlimab + Lenvatinib was added in Amendment 01 on 20-Oct-2020, and enrollment is ongoing. Arm 5: Coformulation Favezelimab/Pembrolizumab was added in Amendment 03 on 01-DEC-2022 and has paused enrollment, Arm 6: Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA) was added in Amendment 03 on 01-DEC-2022 and has paused enrollment, and Arm 7: Coformulation Favezelimab/Pembrolizumab + Vibostolimab was added in Amendment 03 on 01-DEC-2022 and enrollment was stopped prematurely on 22-SEP-2023.
Recruiting1 award Phase 1 & 28 criteria
RP1 + Nivolumab
for Cancer
This trial tests a modified virus (RP1) and an immune-boosting drug (nivolumab) in adults with advanced or treatment-resistant solid tumors. RP1 kills cancer cells and helps the immune system recognize them, while nivolumab enhances the immune response. Nivolumab has been approved for treating advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and other malignancies.
Recruiting1 award Phase 29 criteria
Disitamab Vedotin + Pembrolizumab
for Bladder Cancer
This trial is testing a new drug called disitamab vedotin, alone or with pembrolizumab, for patients with advanced or metastatic HER2 expressing bladder cancer. Disitamab vedotin is designed to target HER2 and has been approved for other types of cancer. The study aims to see if these drugs can effectively treat the cancer and what side effects they might cause.
Recruiting1 award Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at NYU School of Medicine's Kaplan Comprehensive Cancer Center?
NYU School of Medicine's Kaplan Comprehensive Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Lymphoma, Breast Cancer, Brain Tumor, Solid Tumors, Ovarian Cancer and other specialties. NYU School of Medicine's Kaplan Comprehensive Cancer Center is involved with conducting 273 clinical trials across 166 conditions. There are 6 research doctors associated with this hospital, such as Paul Oberstein, MD, Janice M. Mehnert, Kristen Spencer, MD, and Elaine Shum, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.